Download PDF
Thromb Haemost 1994; 72(05): 722-727
DOI: 10.1055/s-0038-1648948
Original Article
Schattauer GmbH Stuttgart

Study of the Interaction of Dextran and Enoxaparin on Haemostasis in Humans

Stefan E Matthiasson
1   The Department of Surgery, Lund University, Malmö General Hospital, Malmö, Sweden
,
Bengt Lindblad
1   The Department of Surgery, Lund University, Malmö General Hospital, Malmö, Sweden
,
Thomas Mätzsch
1   The Department of Surgery, Lund University, Malmö General Hospital, Malmö, Sweden
,
Jarl Molin
2   Rhöne-Poulenc Rorer, Sweden
,
Peter Qvarfordt
3   Department of Surgery, Helsingborg Hospital, Helsingborg, Sweden
,
David Bergqvist
4   Department of Surgery, Uppsala University, University Hospital, Uppsala, Sweden
› Author Affiliations
Further Information

Publication History

Received 03 May 1994

Accepted after revision 26 July 1994

Publication Date:
06 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The effect on haemostatic variables by dextran 70, enoxaparin and their combinations, given in doses of 500 ml i.v. and 40 mg s.c. respectively, was studied in a randomised cross-over fashion in twelve healthy male volunteers. Antifactor-IIa activity, antifactor-Xa activity, APTT, factor VIII, vWF, bleeding time and blood counts were analysed over a 24-h period. Dextran alone did not affect antifactor-IIa activity and antifactor-Xa activity. No difference in antifactor-IIa and antifactor-Xa activity was found for Amax, tmax, AUC0-8 h and AUC0-24 h in the groups treated with enoxaparin or the combination of enoxaparin and dextran. Only minor changes in APTT were observed without statistical significance between the treatment groups. Factor VIII did not change significantly in the three treatment groups. However, vWF was significantly reduced in the dextran and the dextran/enoxaparin group (p = 0.046 and 0.01 respectively) but no difference was found between the two groups. Bleeding time was not significantly increased four hours after administration of the test substances and no difference was found between the individual treatment groups. Our findings indicate that dextran can be combined with enoxaparin, when used in thromboprophylactic doses, without increased risk for bleeding.

 

  • References

  • 1 Bergqvist D. Postoperative thromboembolism; frequency, etiology, prophylaxis. Springer Verlag; Berlin: 1983
    Google Scholar
  • 2 Nicolaides AN. Prevention of venous thromboembolism. European consensus statement. Inter Angio 1992; 11: 151-159
    PubMedGoogle Scholar
  • 3 Jørgensen LN, Wille-Jørgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993; 80: 689-704
    CrossrefPubMedGoogle Scholar
  • 4 Bergqvist D. Review of clinical trials of low molecular weight heparins. Clinical review. Eur J Surg 1992; 158: 67-78
    PubMedGoogle Scholar
  • 5 Bendetowicz AV, Bara L, Samama MM. The inhibition of intrinsic prothrombinase and its generation by heparin and four dérivâtes in prothrombin poor plasma. Thromb Res 1990; 58: 445-454
    CrossrefPubMedGoogle Scholar
  • 6 Lindahl AK, Abildgaard U, Larsen ML, Aamodt LM, Nordfang O, Beck TC. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res (suppl) 1991; 14: 39-48
    PubMedGoogle Scholar
  • 7 Walenga JM, Hoppensteadt DA, Fareed J. Laboratory monitoring of the clinical effects of low molecular weight heparins. Thromb Res (suppl) 1991; 14: 49-62
    PubMedGoogle Scholar
  • 8 Grönwall A, Ingelman B. Dextran as a substitute for plasma. Nature 1945; 155: 45
    PubMedGoogle Scholar
  • 9 Borgström S, Gelin LE, Zederfeldt B. The formation of vein thrombi following tissue injury. Acta Chir Scand (suppl) 1959; 247: 01-36
    PubMedGoogle Scholar
  • 10 Koekenberg L. Experimental use of macrodex as a prophylaxis against postoperative thromboembolism. Excerpta Med Amst 1961; 1961: 123-130
    PubMedGoogle Scholar
  • 11 Bergentz SE, Eiken O, Nilsson IM. The effect of dextran of various molecular weight on the coagulation in dogs. Thromb Diath Haemorrh 1961; 6: 15-24
    PubMedGoogle Scholar
  • 12 Nilsson IM, Eiken O. Further studies on the effect of dextran of various molecular weight on the coagulation mechanism. Thromb Diath Haemorrh 1964; 11: 38-50
    PubMedGoogle Scholar
  • 13 Kladetzky RG, Popov CS, Müller N, Hack G, Lang U. The effect of dextran 70 on the intra- and postoperative behaviour of haemostasis. Bibl Anat 1977; 16: 463-465
    PubMedGoogle Scholar
  • 14 Åberg M, Hedner U, Bergentz SE. Effect of dextran on factor VIII (Antihemophilic Factor) and platelet function. Ann Surg 1979; 189: 243-247
    CrossrefPubMedGoogle Scholar
  • 15 Arfors K-E, Bergqvist D. Microvascular haemostatic plug formation in the rabbit mesentery. Effect of blood flow velocity, thrombocytopenia and dextran treatment. Bibl Haematol 1975; 41: 84-97
    PubMedGoogle Scholar
  • 16 Bergqvist D. The influence of plasma volume expanders on initial haemostasis in the rabbit mesentery. Acta Anaesthesiol Scand 1985; 29: 607-609
    CrossrefPubMedGoogle Scholar
  • 17 Cronberg S, Robertson B, Nilsson IM, Niléhn JE. Suppressive effect of dextran on platelet adhesiveness. Thromb Diath Haemorrh 1966; 16: 384-394
    PubMedGoogle Scholar
  • 18 Holst J, Lindblad B, Mätzsch T, Bergqvist D. Effect on primary haemostasis of prophylactic regimes of low molecular weight heparin, unfractionated heparin, dextran and their combinations. An animal experimental study. Thromb Res 1992; 65: 651-656
    CrossrefPubMedGoogle Scholar
  • 19 Matthiasson SE, Lindblad B, Mätzsch T, Holst J, Bergqvist D. Effect of low molecular weight heparin, dextran and their combinations on experimental venous thrombosis in rabbits. Thromb Haemost 1994; 71: 363-365
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Richter WA, Hedin HI. Dextran hypersensitivity. Immunol Today 1982; 3: 132-138
    CrossrefPubMedGoogle Scholar
  • 21 Müller KH. Comparative studies on the influence of plasma substitutes on coagulation in vivo. Bibl Haematol 1969; 33: 434-451
    PubMedGoogle Scholar
  • 22 Stibbe J, van der Plas PM, Ong GL, ten Hoor F, Nauta J, de Jong DS, Krenning Douma E, Gomes M. Effects of the gelatin plasma substitutes; Haemaccel®, Plasmagel® and Plasmion® (Geloplasma®) on collagen-, ADP- and adrenalin induced aggregation of human platelets in vitro. Haemostasis 1981; 10: 276-288
    PubMedGoogle Scholar
  • 23 Lundsgaard-Hansen P, Tschirren B. Modified fluid gelatin as a plasma substitute. Blood Subst Plasma Expand 1978; 1: 227-257
    PubMedGoogle Scholar
  • 24 Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416
    CrossrefPubMedGoogle Scholar
  • 25 Rosén S. Assay of factor VIILC with a chromogenic substrate. Scand J Haematol (suppl) 1984; 33: 139-145
    PubMedGoogle Scholar
  • 26 Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1972; 29: 21-37
    CrossrefPubMedGoogle Scholar
  • 27 Dunnett CM. A multiple comparison procedure for comparing several treatment with a control. Am Stat Ass J 1955; 50: 1096-1121
    PubMedGoogle Scholar
  • 28 Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res 1984; 35: 613-625
    CrossrefPubMedGoogle Scholar
  • 29 Samama M, Bernard P, Bonnardot JP, Combe TS, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. (Genox multicentric trial.) Br J Surg 1988; 75: 128-131
    CrossrefPubMedGoogle Scholar
  • 30 Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989; 62: 940-944
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929
    CrossrefPubMedGoogle Scholar
  • 32 Leclerc JR, Geerts WH, Desjardings L, Jobin F, Laroche F, Delorme F, Haviemick S, Atkinson S, Bourgouin J. Prevention of deep vein thrombosis after major knee surgery - A randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992; 67: 417-423
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Hammarsten JF, Heller BI. The effects of dextran in subjects with normal blood volumes and in subjects after bleeding. J Lab Clin Med 1952; 40: 807
    PubMedGoogle Scholar
  • 34 Køster KH, Schwartz M, Sele V, Sindrup E. Blood-volume changes after infusion of dextran solutions. Lancet 1957; 2: 262-265
    PubMedGoogle Scholar
  • 35 Bloom WL, Harmer DS, Bryant MF, Brewer SS. Coating of vascular surfaces and cells. A new concept in prevention of intravascular thrombosis. Proc Soc Exp Biol Med 1964; 115: 384-386
    CrossrefPubMedGoogle Scholar
  • 36 Ross S, Ebert R. Microelectrophoresis of blood platelets and the effect of dextran. J Clin Invest 1959; 38: 155-160
    CrossrefPubMedGoogle Scholar
  • 37 Corley RD, Joseph NR. Red cell charge as affected by low viscosity dextran. Proc Soc Exp Biol Med 1966; 122: 1171-1174
    CrossrefPubMedGoogle Scholar
  • 38 Sawyer PN, Stanczewski B, Pomerance A, Lucas T, Stoner G, Srinivasan S. Utility of anticoagulant drugs in vascular thrombosis: Electron microscopy and biophysical study. Surgery 1973; 74: 263-275
    PubMedGoogle Scholar
  • 39 Tangen O, Wik KO, Almqvist IAM, Arfors KE, Hint HC. Effects of dextran on the structure and plasmin-induced lysis of human fibrin. Thromb Res 1972; 1: 487-492
    CrossrefPubMedGoogle Scholar
  • 40 Aberg M. Thesis: On effect of dextran on lysability and structure of ex vivo thrombi, platelet function and factor VIII. Lund University, Malmo General Hospital 1978
    Google Scholar
  • 41 Aberg M, Rausing A. The effect of dextran 70 on the structure of ex vivo thrombi. Thromb Res 1978; 12: 1113-1122
    CrossrefPubMedGoogle Scholar
  • 42 Gelin LE, Thoren O. Influence of low viscous dextran on peripheral circulation in man. A plethysmographic study. Acta Chir Scand 1961; 122: 303-308
    PubMedGoogle Scholar
  • 43 Thorsen G, Hint H. Aggregation, sedimentation and intravascular sludging of erythrocytes. An experimental study. Acta Chir Scand (suppl) 1950; 154: 01-51
    PubMedGoogle Scholar
  • 44 Bennett PN, Dhall DP, McKenzie FN, Matheson NA. Effects of dextran infusion on the adhesiveness of human blood platelets. Lancet 1966; 2: 1001-1003
    PubMedGoogle Scholar
  • 45 Arfors K-E, Hint HC, Dhall DP, Matheson NA. Counteraction of platelet activity at sites of laser-induced endothelial trauma. Br Med J 1968; 4: 430-431
    CrossrefPubMedGoogle Scholar
  • 46 Sobel M, Adelman B, Greenfield LJ. Dextran 40 reduces heparin-mediated platelet aggregation. J Surg Res 1986; 40: 382-387
    CrossrefPubMedGoogle Scholar
  • 47 Frydman AM, Bara L, Le RY, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988; 28: 609-618
    CrossrefPubMedGoogle Scholar
  • 48 Buckley MM, Sorkin EM. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992; 3: 465-497
    PubMedGoogle Scholar
  • 49 Holmberg L, Rasovic N, Nilsson IM. Von Willebrand’s disease with normal factor VIII activity in a homozygote. Haemostasis 1974; 3: 237-246
    PubMedGoogle Scholar
  • 50 Ruggeri ZM. Functional domain of von Willebrand’s factor involved in interactions in platelet and the subendothelium. Prog Clin Biol Res 1988; 183: 219-252
    PubMedGoogle Scholar